RNA (Atrium Therapeutics) NonCurrent Deferred Liabilities: $36.35 Mil (As of Mar. 2026)


RNA Atrium Therapeutics Inc RNA
12 GF Score
Price $13.30
! 1 Warning Sign
View Full Analysis

What is Atrium Therapeutics NonCurrent Deferred Liabilities?

Atrium Therapeutics RNA -0.97% 12 NonCurrent Deferred Liabilities is $36.35 Mil as of Mar. 2026. GuruFocus rates RNA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Atrium Therapeutics's non-current deferred liabilities for the quarter that ended in Mar. 2026 was $36.35 Mil.

Atrium Therapeutics NonCurrent Deferred Liabilities Related Terms

Atrium Therapeutics NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Atrium Therapeutics's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atrium Therapeutics NonCurrent Deferred Liabilities Chart

Atrium Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
40.90 37.96 28.69

Atrium Therapeutics Quarterly Data
Dec23 Dec24 Mar25 Sep25 Dec25 Mar26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial 37.96 0.00 32.07 28.69 36.35
RNA
12GF Score
Atrium Therapeutics Inc RNA
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of $36.35 Mil mean?
Atrium Therapeutics (RNA) has a NonCurrent Deferred Liabilities of $36.35 Mil as of Mar. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Atrium Therapeutics and its competitors.
Is Atrium Therapeutics' NonCurrent Deferred Liabilities too high?
Atrium Therapeutics' current NonCurrent Deferred Liabilities is $36.35 Mil. Overall, Atrium Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Atrium Therapeutics' NonCurrent Deferred Liabilities compare to CNTN and QTTB?
Atrium Therapeutics' NonCurrent Deferred Liabilities of $36.35 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Atrium Therapeutics and its competitors. Atrium Therapeutics's current NonCurrent Deferred Liabilities is $36.35 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrium Therapeutics stock overvalued right now?
Atrium Therapeutics (RNA) has a current NonCurrent Deferred Liabilities of $36.35 Mil. The current NonCurrent Deferred Liabilities is $36.35 Mil. Atrium Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Atrium Therapeutics (RNA), the current NonCurrent Deferred Liabilities is $36.35 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Atrium Therapeutics Business Description

Address 10578 Science Center Drive, Suite 125, San Diego, CA, USA, 92121
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
12GF Score

Get the complete analysis for RNA

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.30
Price